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Several drugs are known to cause a lupus-type syndrome.1 Methyldopa causes
positive anti-nuclear antibody reactions, but only two previously reported cases
of a methyldopa-induced lupus-type syndrome have been described.23 We
report a case of this syndrome which failed to resolve fully on withdrawal of the
drug, and which has features of a mixed connective tissue disorder (MCTD).
CASE HISTORY
A 78-year-old woman presented in March 1985 with myalgia, arthralgia, loss of
energy and postural dizziness. Drug therapy prior to admission was methyldopa
500 mg three times daily and cyclopenthiazide 500 pg daily, which she had
taken for four years for 'hypertension', and naftidrofuryl oxalate 100 mg three
times daily.
On examination she had severe postural hypotension (supine blood pressure
140/80 mmHg, erect 80/40 mmHg), generalised muscle tenderness, marked
leg oedema and ascites. The ESR was 106 mm/hour, Hb 11.7 g/dl, WCC
13.1 x 109/1 (eosinophils 2.22 x 109/1), urea and electrolytes normal, total
protein 49 g/l, alkaline phosphatase 62 u/I, aspartate transaminase 28 u/I,
alanine transaminase 13 u/l and gammaglutamyltransferase 5 u/l. Plasma
protein electrophoresis showed generalised hypergammaglobulinaemia. Serum
creatinine was 123 pmol/l, creatinine clearance 30 ml/min, urinary protein
output 0.14 g/24 hours. Serum C3 and C4 complement levels were normal. Anti-
nuclear antibodies (ANA) were present, titre 1:320 (IgG class, diffuse pattern)
but antibodies to double-stranded DNA and to ribonucleoprotein were negative.
The chest X-ray showed a moderate right-sided pleural effusion.
All her drugs were stopped and, at review one month later, her postural
hypotension had resolved. The ESR was 30 mm/hour, the WCC 10.9 x 109/1
(eosinophils 0.26 x 109/1) and the total serum protein had risen to 63 g/l. The
pleural effusion had resolved radiologically and the ascites had cleared. At this
review, she had severe Raynaud's phenomenon and complained of 'taut, tight
skin' on hands and feet. There was a violaceous rash on the extensor surfaces of
elbows and knees and around the eyes suggestive of dermatomyositis. There
were discrete telangiectatic areas over the hands, and the skin appeared
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thickened, tight and shiny over hands, forearms and knees. A skin biopsy showed
oedema only and was negative for immunofluorescent antibody staining. Despite
this, the clinical appearances were typical of sclerodermatous change. Barium
swallow demonstrated oesophageal hypomotility and pooling of barium in the
erect position suggesting systemic involvement. X-rays of both hands were
negative for soft tissue calcification.
COMMENT
A drug-induced lupus-type syndrome was first associated with hydrallazine in
1953.4 Since then, over 30 drugs have been implicated,5 the commonest being
hydrallazine and procainamide.1 As far as we are aware, this is only the third
reported case of methyldopa-induced lupus-type syndrome.
In contrast with systemic lupus erythematosus, drug-induced lupus is commoner
in older patients and tends to run a benign clinical course. Renal and neurological
involvement is rare and the clinical syndrome usually remits following withdrawal
of the offending drug. Our patient had certain unusual features of the drug-
induced lupus syndrome. Although her pleural effusion and ascites resolved
spontaneously followingdrugwithdrawal, sherapidlydeveloped severeRaynaud's
phenomenon andcutaneous featuresofscleroderma and dermatomyositis. These
have persisted for nine months following withdrawal and she remains positive for
ANA. This contrasts with most reported cases of drug-induced lupus in which
symptomsand signs have remitted promptlyfollowing drug withdrawal. However,
in one of the two previously reported cases the positive ANA persisted for three
months following drug withdrawal, though in this case the clinical syndrome itself
resolved rapidly within two weeks of drug withdrawal.2 The fact that the positive
ANA can persist indicates that the drug-induced auto-immune condition can also
persist. It is therefore possible that our patient's condition persisted and evolved
into a sclerodermatous condition following withdrawal of the methyldopa.
The combination of arthralgia, myalgia, Raynaud's phenomenon, oesophageal
hypomotility and cutaneous features of scleroderma and dermatomyositis raises
the possibility of mixed connective tissue disease despite the fact that serum was
repeatedly negative for ribonucleoprotein antibodies.
Seroconversion to positive ANA has occurred in the known cases of methyldopa-
induced lupus syndrome after variable periods of drug exposure. Breckenridge et
al showed that ANA positively rises with duration of treatment.6 In the two
previously reported cases, the duration of treatment before seroconversion was
two years and one year respectively2'3 and in our patient it was four years. The
development ofANA and the lupus-type syndromein patients taking methyldopa
is therefore probably dose-related. Inhibition of suppressor T cell functions by
methyldopa has been demonstrated and may be one of the factors responsible.7
This patient demonstrates some unusual features of methyldopa-induced lupus
syndrome and is only the third reported case. The clinical presentation and
progress raises the possibility of an associated mixed connective tissue disease.
We cannot recommend the use of methyldopa as an anti-hypertensive agent in
the elderly because of its association, in our experience, with central nervous
system depression, postural hypotension, haemolytic anaemia, cholestatic
jaundice and now a lupus-type syndrome.
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